Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 1.00 |
| ▸ | FNTA | P49354 | 6/20 | 0.42 |
| ▸ | FNTB | P49356 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dapitant SCHEMBL6437147 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL14071561 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL7582571 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL13575759 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL30695498 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL6908668 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL7768046 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| Dapitant SCHEMBL8543936 | 1.00 | TACR1 (1.00) | TACR1FNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8543712 | 0.94 | TACR1 (0.89) | TACR1FNTAFNTBMEN1CYP3A4 | |
| SCHEMBL8956844 | 0.94 | TACR1 (0.89) | TACR1FNTAFNTBMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2341 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| US-12419861-B2 | Method for preventing and/or treating chronic traumatic encephalopathy-i | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-23 | — | — | US | claimed |
| US-20250186427-A1 | METHODS AND COMPOSITIONS FOR TREATING VASOMOTOR SYMPTOMS | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| EP-4461362-A2 | NK1-ANTAGONIST COMBINATION AND METHOD FOR TREATING SYNUCLEINOPATHIES | Chase Therapeutics Corporation (US) | 2024-11-13 | — | — | EP | claimed |
| WO-2024194352-A1 | DEUTERATED P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-26 | — | — | WO | claimed |
| US-20240299404-A1 | TREATMENT OF PRURITUS WITH P2X3 MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2024-09-12 | — | — | US | claimed |
| US-20240252484-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2024-08-01 | — | — | US | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| EP-4103564-A1 | P2X3 MODULATORS | Bellus Health Cough Inc. (CA) | 2022-12-21 | — | — | EP | claimed |
| EP-1299100-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | THE UNIVERSITY OF ROCHESTER (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | claimed |
| US-6525073-B2 | For achieving circadian rhythm phase-shifting effect in mammal | MERCK & CO. INC. | 2003-02-25 | — | — | US | claimed |
| US-20020035059-A1 | Prevention or treatment of insomina with a neurokinin-1 receptor antagonist | MERCK & CO., INC. | 2002-03-21 | — | — | US | claimed |
| US-20020016283-A1 | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist | UNIVERSITY OF ROCHESTER | 2002-02-07 | — | — | US | claimed |
| WO-2001095904-A1 | METHOD OF TREATING SYMPTOMS OF HORMONAL VARIATION, INCLUDING HOT FLASHES, USING TACHYKININ RECEPTOR ANTAGONIST | UNIVERSITY OF ROCHESTER (US) | 2001-12-20 | — | — | WO | claimed |
| US-6329401-B1 | PREVENTION OR TREATMENT OF SLEEP DISORDER; BY ADMINISTERING A CNS PENETRATING NEUROKININ-1 RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-12-11 | — | — | US | claimed |
| US-6274604-B1 | ADMINISTERING A NEUROKININ-1 RECEPTOR ANTAGONIST TO ACHIEVE A CIRCADIAN RYTHM PHASE-SHIFTING TO IMPROVE THE QUALITY OF SLEEP | MERCK & CO., INC. | 2001-08-14 | — | — | US | claimed |
| US-6177450-B1 | MIXTURE OF PERHYDROISOINDENE COMPOUND AND BENEZAMIDE COMPOUND | AVENTIS PHARMA S.A. | 2001-01-23 | — | — | US | claimed |
| US-6034105-A | NEUROKININ RECEPTOR ANTAGONIST; SLEEP DISORDERS | MERCK & CO., INC. (US) | 2000-03-07 | — | — | US | claimed |